This roundtable series covers molecular imaging, prostate-specific membrane antigen testing, and treatment options for patients with castration-resistant prostate cancer discussed in virtual live events.
Srinivas Reviews Data of Hormonal Agents in the nmCRPC Setting
October 15th 2021During a virtual live event with other physicians, Sandy Srinivas, MD, reviewed data for 3 antiandrogens used for patients with nonmetastatic castration-resistant prostate cancer, including apalutamide, darolutamide, and enzalutamide.
Part 4: Discussing the Use of PET Scans and Metastatic Disease in CRPC
November 2nd 2021Tanya Dorff, MD, asks the participants of a roundtable discussion about their opinion survival data of androgen receptor–targeted therapy and treating patients with PET scan-only metastatic castration-resistant prostate cancer.
Part 3: Combining Therapies to Treat a Patient With CRPC
November 10th 2021During a live virtual event, Alicia Morgans, MD, MPH, discussed when to combine novel hormonal agents with androgen-deprivation therapy in nonmetastatic castrate-resistant prostate cancer and how novel imaging techniques could influence treatment.
Part 1: Deciding Whether Next-Generation Scans Are Needed for nmCRPC
February 18th 2022During a live event, Evan Yu, MD, discussed how to monitor a patient being treated with androgen deprivation therapy and hormonal agents for nonmetastatic castration-resistant prostate cancer using prostate-specific antigen levels and next-generation imaging.